Maravai Lifesciences Holdings Inc (MRVI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Maravai Lifesciences Holdings Inc (MRVI) has a cash flow conversion efficiency ratio of 0.011x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.99 Million) by net assets ($355.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Maravai Lifesciences Holdings Inc market capitalisation for the company's overall valuation and market capitalisation.
Maravai Lifesciences Holdings Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Maravai Lifesciences Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Maravai Lifesciences Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maravai Lifesciences Holdings Inc ranked by their cash flow conversion efficiency. Explore MRVI cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MBB INDUSTRIES
XETRA:MBB
|
0.067x |
|
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
|
0.053x |
|
Eerly Govt Ppty Inc
NYSE:DEA
|
0.020x |
|
Huludao Zinc Industry Co Ltd
SHE:000751
|
0.108x |
|
CONMED Corporation
NYSE:CNMD
|
0.013x |
|
Dongwon Ind
KO:006040
|
0.044x |
|
Jiangsu Libert Inc
SHG:605167
|
0.005x |
|
NPK International Inc.
NYSE:NPKI
|
0.059x |
Annual Cash Flow Conversion Efficiency for Maravai Lifesciences Holdings Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Maravai Lifesciences Holdings Inc from 2018 to 2025. View Maravai Lifesciences Holdings Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $372.71 Million | $-57.57 Million | -0.154x | -1294.40% |
| 2024-12-31 | $577.21 Million | $7.46 Million | 0.013x | -91.91% |
| 2023-12-31 | $789.88 Million | $126.22 Million | 0.160x | -73.01% |
| 2022-12-31 | $905.24 Million | $535.98 Million | 0.592x | -12.39% |
| 2021-12-31 | $545.36 Million | $368.57 Million | 0.676x | -31.28% |
| 2020-12-31 | $154.75 Million | $152.19 Million | 0.983x | +489.82% |
| 2019-12-31 | $144.63 Million | $24.11 Million | 0.167x | +13368.86% |
| 2018-12-31 | $148.02 Million | $-186.00K | -0.001x | -- |
About Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products fo… Read more